{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:00:06Z","timestamp":1790384406912,"version":"4.1.0"},"reference-count":43,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Previous studies of guselkumab have demonstrated clinical benefits in patients with plaque\u2010type psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and palmoplantar pustulosis (PPP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this exploratory analysis of a double\u2010blind, multicenter, placebo\u2010controlled, phase 3 study in Japanese patients with PPP was to evaluate the efficacy of guselkumab in the subset of patients with pustulotic arthro\u2010osteitis (PAO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were randomized to receive guselkumab 100 or 200\u00a0mg at weeks 0, 4, 12 and every 8\u00a0weeks, or placebo with cross\u2010over to guselkumab 100 or 200\u00a0mg at week 16 (placebo group). Efficacy endpoints were changes from baseline in magnetic resonance imaging (MRI) score, EuroQOL\u20105 dimensions (EQ\u20105D) index score, EQ\u20105D pain\/discomfort dimension score and C\u2010reactive protein (CRP, mg\/L) level in all PAO patients through week 52. Data from both guselkumab groups were combined and presented as results for a single overall guselkumab group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 159 patients with PPP, 66 with PAO were randomized across treatment groups. For patients with MRI data for all regions assessed, the proportion of patients in the guselkumab group with PAO characterized as severe decreased from 23.8% (10\/42) at baseline to 5.4% (2\/42) at week 52. The mean (SD) change from baseline at week 52 in EQ\u20105D index score was 0.20 (0.17) among PPP patients with PAO and 0.15 (0.17) among those without PAO in the guselkumab group. Among all PAO patients, the proportions with an EQ\u20105D pain\/discomfort dimension score of no or slight pain\/discomfort in the guselkumab group increased from baseline to week 52 [33.3% (7\/21) vs. 87.5% (35\/40)]. The mean (SD) CRP levels decreased in all PAO patients in the guselkumab group at week 52 compared to baseline [\u22121.71 (8.16)\u00a0mg\/L].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Guselkumab treatment showed beneficial outcomes for PAO signs and symptoms in Japanese patients with PPP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.16355","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T03:57:42Z","timestamp":1584331062000},"page":"2318-2329","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Efficacy of guselkumab in a subpopulation with pustulotic arthro\u2010osteitis through week 52: an exploratory analysis of a phase 3, randomized, double\u2010blind, placebo\u2010controlled study in Japanese patients with palmoplantar pustulosis"],"prefix":"10.1111","volume":"34","author":[{"given":"T.","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Dermatology Fukushima Medical University Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Radiology The Jikei University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Geriatric and Environmental Dermatology Nagoya City University Graduate School of Medical Sciences Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2903-4920","authenticated-orcid":false,"given":"T.","family":"Kimura","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutical K.K Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Morishima","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutical K.K Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Goto","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutical K.K Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Zheng","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutical K.K Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Terui","sequence":"additional","affiliation":[{"name":"Department of Dermatology Nihon University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.5937"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-00745-6"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1977.tb01011.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.80417"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12272"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.55.3.177"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14187"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12223"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-1335-3"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1998.tb02381.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.40.6.554"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2001.00759.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.168"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2011.01325.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.1.669"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1112-x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.03.004"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14294"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302853"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-018-0265-6"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000147"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1698"},{"key":"e_1_2_8_26_1","unstructured":"Janssen announces US FDA approval of Tremfya\u2122 (guselkumab) for the treatment of moderate to severe plaque psoriasis.2017. URLhttps:\/\/www.jnj.com\/media\u2010center\/press\u2010releases\/janssen\u2010announces\u2010us\u2010fda\u2010approval\u2010of\u2010tremfya\u2010guselkumab\u2010for\u2010the\u2010treatment\u2010of\u2010moderate\u2010to\u2010severe\u2010plaque\u2010psoriasis(last accessed 27 March 2019)."},{"key":"e_1_2_8_27_1","unstructured":"European medicines agency.Tremfya\u2010guselkumab.2017. URL:https:\/\/www.ema.europa.eu\/medicines\/human\/EPAR\/tremfya(last accessed 27 March 2019)."},{"key":"e_1_2_8_28_1","unstructured":"MorphoSys announces approval of Tremfya(R) (Guselkumab) for the treatment of moderate to severe forms of psoriasis and psoriatic arthritis in Japan.2018. URLhttps:\/\/www.morphosys.com\/media\u2010investors\/media\u2010center\/morphosys\u2010announces\u2010approval\u2010of\u2010tremfyar\u2010guselkumab\u2010for\u2010the\u2010treatment(last accessed 30 November 2018). 2018."},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16236"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30952-8"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14504"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.1394"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110420"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.031773"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090352"},{"key":"e_1_2_8_36_1","first-page":"1385","article-title":"Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA\u2010MRI scoring system","volume":"30","author":"Ostergaard M","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.5152\/eurasianjmed.2018.17268"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.3233\/BMR-169646"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14717"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14131"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2013.07.016"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2817"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209068"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61134-4"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.16355","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16355","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.16355","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T07:45:37Z","timestamp":1693813537000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.16355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1111\/jdv.16355"],"URL":"https:\/\/doi.org\/10.1111\/jdv.16355","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737572681.793586750","asserted-by":"object"}]},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,15]]},"assertion":[{"value":"2019-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}